Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew, Zijun Wang, Shlomo Finkin, Christian Gaebler, Victor Ramos, Melissa Cipolla, Pilar Mendoza, Marianna Agudelo, Eva Bednarski, Justin DaSilva, Irina Shimeliovich, Juan Dizon, Mridushi Daga, Katrina G. Millard, Martina Turroja, Fabian Schmidt, Fengwen Zhang, Tarek Ben TanfousMila Jankovic, Thiago Y. Oliveria, Anna Gazumyan, Marina Caskey, Paul D. Bieniasz, Theodora Hatziioannou, Michel C. Nussenzweig

Research output: Contribution to journalArticlepeer-review

176 Scopus citations


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During that time, memory B cells express increasingly broad and potent antibodies that are resistant to mutations found in variants of concern1. As a result, vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines produces high levels of plasma neutralizing activity against all variants tested1,2. Here we examine memory B cell evolution five months after vaccination with either Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) mRNA vaccine in a cohort of SARS-CoV-2-naive individuals. Between prime and boost, memory B cells produce antibodies that evolve increased neutralizing activity, but there is no further increase in potency or breadth thereafter. Instead, memory B cells that emerge five months after vaccination of naive individuals express antibodies that are similar to those that dominate the initial response. While individual memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination, the overall neutralizing potency of plasma is greater following vaccination. These results suggest that boosting vaccinated individuals with currently available mRNA vaccines will increase plasma neutralizing activity but may not produce antibodies with equivalent breadth to those obtained by vaccinating convalescent individuals.
Original languageEnglish (US)
Pages (from-to)517-522
Number of pages6
Issue number7889
StatePublished - Dec 16 2021
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination'. Together they form a unique fingerprint.

Cite this